Navigation Links
Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease
Date:10/19/2010

nistration of CERE-120 to both the substantia nigra as well as the putamen. Once CERE-120 is delivered to the brain, it provides stable, long-lasting expression of neurturin in a highly targeted fashion.

About Parkinson's Disease

Parkinson's disease is a progressive movement disorder that affects a million people in the United States. Its main symptoms, stiffness, tremors and slowed movements and gait, are caused by a loss of dopamine-containing nerve cells in the substantia nigra, which project their axons to the putamen. Dopamine is a neurotransmitter involved in controlling movement and coordination, so Parkinson's patients exhibit a progressive inability to initiate and control physical movements. There is currently no treatment that can reverse the degeneration of these neurons, let alone cure Parkinson's disease.

About Ceregene

Ceregene, Inc. is a San Diego-based biotechnology company focused on the delivery of nervous system growth (neurotrophic) factors for the treatment of neurodegenerative and retinal disorders using gene delivery. Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor (NGF) currently in a multi-center, controlled Phase 2 study for the treatment of Alzheimer's disease (in collaboration with the ADCS), and CERE-120 (AAV2-Neurturin) for Parkinson's disease. Ceregene was launched in January 2001. The company's investors include Alta Partners, MPM Capital, Hamilton BioVentures, Investor Growth Capital, California Technology Partners and BioSante Pharmaceuticals (Nasdaq: BPAX) which acquired its position following its merger with Cell Genesys, Inc. in October 2009.

About The Michael J. Fox Foundation

The Michael J. Fox Foundation for Parkinson's Research is dedicated to finding a cure for Parkinson's disease through an aggressively funde
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinsons Disease
2. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
3. Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)
4. Echo Therapeutics Initiates Needle-Free Biosensor Program for Continuous Lactate Monitoring
5. LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine
6. ISTA Pharmaceuticals Initiates Phase 3 Clinical Program for REMURA™ in Dry Eye Disease
7. N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
8. Vanda Pharmaceuticals Initiates Phase III Clinical Study Aimed at Resetting the Body Clock
9. Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients
10. Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3
11. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... DUBLIN , Aug. 4, 2015 /PRNewswire/ ... announced the addition of Jain PharmaBiotech,s new ... Markets, and Companies" to their offering. ... transdermal drug delivery - an approach used ... therapeutic use as an alternative to oral,intravascular, ...
(Date:8/4/2015)... York , August 4, 2015 ... titled " Non-invasive Prenatal Testing (NIPT) Market (BambniTest, Harmony, ... Others) - Global Industry Analysis, Size, Volume, Share, Growth, ... According to a new market report published by Transparency ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ...
(Date:8/4/2015)... Organovo Holdings, Inc. (NYSE MKT: ONVO; ... scientific and medical breakthroughs using 3D bioprinting technology, ... Paul Gallant as its General Manager of ... Gallant has more than 20 years of management ... most recently serving as chief operating officer for ...
Breaking Medicine Technology:Transdermal Drug Delivery Report 2015-2024 - Technologies, Markets, and Companies Analysis 2Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 2Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 3Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 4Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 5Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 3
(Date:8/4/2015)... St. Louis, Missouri (PRWEB) , ... August 04, ... ... Automated Texting (IAT) solutions, today announced that Bruce McCalley joins its executive leadership ... 30-year track record of sales success at technology companies and expanding global markets ...
(Date:8/4/2015)... ... , ... Montclair State University and Atlantic Health System have launched a new ... Jersey, which starting this Fall will help prepare those entering this burgeoning, hybrid field. ... System, one of the largest health care organizations in New Jersey, to design the ...
(Date:8/4/2015)... ... August 04, 2015 , ... It’s been called “cosmetics ... the customer experience inside Naimie’s Beauty Center in LA. Now MENAJI is part of ... look better. , Naimie’s Beauty Center has been a favorite of makeup artists and ...
(Date:8/4/2015)... (PRWEB) , ... August 04, ... ... its HealthCenter personal health record (PHR) product has achieved Office of the ... Inpatient EHR Certification from Drummond Group. HealthCenter delivers the highest quality personal ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... healthcare finance, announced the closing of a $118 million FHA-insured loan modification refinancing ... located in Smithfield and Clayton, North Carolina. JHSC is a joint venture ...
Breaking Medicine News(10 mins):Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 3Health News:MENAJI Shines in Make-Up Mecca for Stars 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3
... Additional beneficial effects on cardiometabolic risk factors beyond those ... drug rimonabant may not be due to the drug ... Drug and Therapeutics Bulletin (DTB). ,Advertisements ... Sanofi-Aventis) claim that an estimated 50% of the effects ...
... Cryo-Save Group NV together with the University of Cologne ... collect adult mesenchymal stem cells ("MSCs") from the ... allows the collection and cryopreservation of very high quantities ... ,Mesenchymal stem cells (MSCs) are of great therapeutic ...
... current rehab spell will bring a stop to her suicidal ... ,As the Mean Girls star checked into the Promises ... arrested for DUI, her supposed friends got ready to reveal ... America's Star magazine that Lohan attempted to take her own ...
... to enter rehab in order to get rid of his addiction ... was recently snapped in a sleazy romp with two hookers, admitted ... ,"Im a bad boy. I go out and get drunk, ... with the wrong women. Ive been sowing my oats for years, ...
... unabated across the Atlantic. But the man who set off ... Denver that specializes in the disease. The man himself ... Atlanta. He is not coughing, has no fever and does ... said. ,Still, staff at the National Jewish Medical ...
... double current funding levels for the President's Emergency Plan ... years after the program's original mandate expires next year, ... $15 billion over five years for HIV/AIDS and tuberculosis ... the Global Fund To Fight AIDS, Tuberculosis and Malaria. ...
Cached Medicine News:Health News:Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned 2Health News:Significant Scientific Breakthrough in Stem Cell Banking 2Health News:American Who Set Off TB Scare Doing Well in Hospital 2Health News:American Who Set Off TB Scare Doing Well in Hospital 3Health News:Bush Announces Request for $30B, Five-Year Extension of PEPFAR 2
... the latest technology and innovative software with ... transmission and auto detection of progressive lenses. ... network with the VELO 8500 Motorized Refractor ... the future. , ,*VELOtm Aculens 186UV can ...
...
...
...
Medicine Products: